Immunovant to Participate in Roivant R&D Day 2021
Rhea-AI Summary
Immunovant, Inc. (Nasdaq: IMVT), a biopharmaceutical company specializing in autoimmune diseases, announced participation by CEO Pete Salzmann, M.D. in a fireside chat at Roivant R&D Day 2021 on September 28, 2021, at 4:00 p.m. ET. The event will be accessible via a live webcast, with a replay available for 30 days afterwards on the company's investor page. Immunovant is advancing IMVT-1401, an innovative treatment targeting diseases caused by harmful IgG antibodies.
Positive
- None.
Negative
- None.
News Market Reaction – IMVT
In the trading session that priced this news, IMVT gained 3.70%, reflecting a moderate positive market reaction.
Data tracked by StockTitan Argus on the day of publication.
AI-generated analysis. How Rhea-AI works. Not financial advice.
NEW YORK, Sept. 27, 2021 (GLOBE NEWSWIRE) -- Immunovant, Inc. (Nasdaq: IMVT), a clinical-stage biopharmaceutical company focused on enabling normal lives for people with autoimmune diseases, today announced that Pete Salzmann, M.D., Chief Executive Officer, will participate in a fireside chat during Roivant R&D Day 2021 on Tuesday, September 28, 2021 at 4:00 p.m. ET.
A live webcast of the event can be accessed at www.tinyurl.com/roivant. A replay of the event will be archived under the ‘Events’ section on the Investors page at www.immunovant.com for 30 days following the presentation.
About Immunovant, Inc.
Immunovant, Inc. is a clinical-stage biopharmaceutical company focused on enabling normal lives for people with autoimmune diseases. Immunovant is developing IMVT-1401, a novel, fully human anti-FcRn monoclonal antibody, as a subcutaneous injection for the treatment of autoimmune diseases mediated by pathogenic IgG antibodies.
Contact:
Tom Dorney, MS, MBA
Director, Investor Relations & Strategy
Immunovant, Inc.
info@immunovant.com
